论文部分内容阅读
目的观察沙格列汀在80岁以上2型糖尿病(T2DM)患者中的药物疗效及安全性,为临床治疗老年糖尿病提供可参考依据。方法选取2014年10月至2015年9月在成都市慢性病医院就诊的16例T2DM血糖控制未达标的年龄>80岁患者为研究对象,在原有降糖药物治疗基础上加用沙格列汀治疗24周,检测治疗前后糖化血红蛋白(Hb A1C)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、体质指数(BMI)、血肌酐(SCr),并观察记录低血糖事件,应用SPSS 13.0软件进行t检验和χ2检验。结果治疗后,T2DM患者Hb A1C、FPG、2 h PG[分别为6.43%±0.38%、(6.8±2.8)mmol/L和(8.6±1.7)mmol/L]均较治疗前[分别为8.31%±1.25%、(8.9±3.4)mmol/L和(14.6±3.4)mmol/L]明显降低,低血糖事件明显减少,差异均有统计学意义(P<0.05),BMI及肾功能治疗前后无明显变化,差异均无统计学意义(P>0.05)。结论沙格列汀与胰岛素制剂、阿卡波糖联合应用具有稳态降糖、减少胰岛素剂量、不增加体重和减少低血糖风险等作用,应用于80岁以上T2DM患者有较高的安全性。
Objective To observe the efficacy and safety of saxagliptin in the treatment of type 2 diabetes mellitus (T2DM) in patients over 80 years old, and provide reference for the clinical treatment of senile diabetes mellitus. Methods Sixteen patients with uncontrolled T2DM whose glycemic control was not over 80 years old who were admitted to Chengdu Chronic Disease Hospital from October 2014 to September 2015 were selected as study subjects. Soglitazin was used on the basis of the original antidiabetic drugs (Hb A1C), fasting blood glucose (FPG), 2 h postprandial blood glucose (2 h PG), body mass index (BMI) and serum creatinine (SCr) were measured before and 24 weeks after treatment. SPSS 13.0 software t test and χ2 test. Results After treatment, Hb A1C, FPG and 2 h PG [6.43% ± 0.38%, (6.8 ± 2.8) mmol / L and (8.6 ± 1.7) mmol / L] in T2DM patients were significantly higher than those before treatment [8.31% ± 1.25%, (8.9 ± 3.4) mmol / L and (14.6 ± 3.4) mmol / L], and the incidence of hypoglycaemia was significantly decreased (P <0.05) Significant changes, the difference was not statistically significant (P> 0.05). Conclusion The combination of saxagliptin with insulin and acarbose has the effect of steady-state hypoglycemic, reducing insulin dosage, not increasing body weight and reducing the risk of hypoglycemia, which is safe for T2DM patients over 80 years of age.